|Webcast - Replay|
Q2 2017 Paratek Pharmaceuticals Inc Earnings Conference Call
08/02/17 at 8:30 a.m. ET
Corporate ProfileParatek is developing and commercializing innovative antibacterial therapeutics based upon tetracycline chemistry. Paratek has used its expertise in microbial biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the tetracycline class of molecules. Paratek’s two lead antibacterial product candidates are omadacycline and sarecycline. Omadacycline entered Phase 3 clinical development in June 2015. Sarecycline entered Phase 3 clinical development in December 2014.
|See More >>|